2 active not recruiting, 1 completed, 1 recruiting. 2 Phase 1, 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 2 |
| Not applicable | 1 | Completed 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Advanced Lung Small Cell Carcinoma: new trials by email Literature Review of Advanced Lung Small Cell Carcinoma trials Research Report on Advanced Lung Small Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer Clinical Encounter, Home Health Encounter, Quality-of-Life Assessment - Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 220 | 2023-08-23 | 2026-04-20 |
| Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial Best Practice, Exercise Intervention, Physical Therapy - Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Small Cell Carcinoma | Not applicable | Completed | Ohio State University Comprehensive Cancer Center | 100 | 2022-04-14 | 2025-11-21 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 8 | 2021-11-22 | 2026-05-28 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer Cisplatin, Elimusertib, Gemcitabine Hydrochloride - Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 74 | 2021-08-25 | 2026-07-31 |
Lung Neoplasms (3) · Ovarian Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Medullary (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · HIV Infections (1) · Melanoma (1) · Mesothelioma, Malignant (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1) · Neoplasm Metastasis (1) · Penile Neoplasms (1)
Neoplasms (4) · Lung Diseases (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3) · Thoracic Neoplasms (3) · Adnexal Diseases (2) · Breast Diseases (2) · Breast Neoplasms (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genital Diseases (2)
1,2-diaminocyclohexaneplatinum II citrate (1) · BAY 1895344 (1) · Cisplatin (1) · Gemcitabine (1) · Home Care Services (1) · House Calls (1) · Magnetic Resonance Spectroscopy (1) · Nivolumab (1) · Physical Therapy Modalities (1) · Platinum (1) · Practice Guidelines as Topic (1) · Relaxation Therapy (1) · Specimen Handling (1) · Standard of Care (1) · cabozantinib (1)
National Cancer Institute (NCI) (2) · Mayo Clinic (1) · Ohio State University Comprehensive Cancer Center (1)
United States (4) · Canada (1)
Carolyn J Presley, MD (1) · Haiying Cheng (1) · Mamta Parikh (1) · Roxana S. Dronca, MD (1)
K76AG074923 (1), UM1CA186717 (1)